People: Furiex Pharmaceuticals Inc (FURX.O)
7 Mar 2014
Dr. Wendy L. Dixon, Ph.D. is Independent Director of Furiex Pharmaceuticals Inc. She was formerly the Chief Marketing Officer and President of Global Marketing for Bristol-Myers Squibb from 2001 to 2009. While at Bristol-Myers Squibb, Dr. Dixon also served on the CEO’s Executive Committee. She has had an over 30-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. From 1996 to 2001 she was Senior Vice President Marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon serves on the boards of directors of Alkermes PLC, Incyte Corporation, Orexigen Therapeutics and formerly on Ardea Biosciences, Inc. (sold to AstraZeneca PLC in 2012) and Dentsply International.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|